Clinical Trials Directory

Trials / Completed

CompletedNCT04304014

Assessment of the Impact of Type of Probiotic, Delivery Type and Feeding Type on Baby's Microbiota After Dysbiotic Delivery

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
119 (actual)
Sponsor
Fundacion Clinic per a la Recerca Biomédica · Academic / Other
Sex
All
Age
25 Days
Healthy volunteers
Not accepted

Summary

This study aims to determine the effect of three factors (delivery type, feeding type and the use of two different dietary supplements) on rebiosis after disbiotic delivery. This is a randomized, single-blinded study with two parallel arms. Group 1 will receive L. reuteri (10\^8 CFU) once a day, group 2 will receive B. longum and P. Pentosaceus (10\^9 CFU) once a day.

Detailed description

Gut colonization during the first days of life represents the start of the infant's own microbiota. This process is influenced by different factors: delivery type, feeding type, antibiotic treatment, etc. On the one hand, vaginally delivered babies are in contact with mother's vaginal and faecal microbiota. This fact will drive a neonatal gut colonization composed of vagina-associated bacteria. In contrast, babies born by C-section are more susceptible to be colonized by microorganisms present in the mother's skin. On the other hand, antibiotic administration during vaginal delivery also produces alterations in the vaginal microbiota of the mother. Described scenarios have been correlated to immunological and metabolic diseases such as asthma, allergies, diabetes or obesity. Moreover, disbiosis has also been associated to functional gastrointestinal disorders (FGID) in babies such as infant colic and functional constipation. After a disbiotic delivery, medical doctors usually recommend the use of probiotics to prevent rebiosis. Since the probiotics. L. reuteri, and B. longum and P. Pentosaceus have shown efficacy on FGID amelioration in previously published articles, these two probiotics were selected for the present study. All together, this study aims to characterize the role of three different parameters: type of probiotic, delivery type and feeding type.

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTL. reuteri(10\^8 CFU) once a day
DIETARY_SUPPLEMENTB. longum and P. Pentosaceus(10\^9 CFU) once a day

Timeline

Start date
2020-03-05
Primary completion
2024-03-12
Completion
2024-11-30
First posted
2020-03-11
Last updated
2025-05-20

Locations

3 sites across 1 country: Spain

Source: ClinicalTrials.gov record NCT04304014. Inclusion in this directory is not an endorsement.